- Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
- Bavarian Nordic indsender supplerende ansøgning til de amerikanske sundhedsmyndigheder om godkendelse af frysetørret koppe- og mpoxvaccine
- Bavarian Nordic og CEPI indgår partnerskab om mpox-vaccinationer i Afrika
- Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
- Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
- Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner
- Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram samt ophør af aktietilbagekøbsprogram
- Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
- Laurence de Moerlooze fratræder som EVP og Chief Medical Officer i Bavarian Nordic
- EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
More ▼
Key statistics
On Friday, Bavarian Nordic A/S (BVNRY:PKL) closed at 8.93, -16.15% below its 52-week high of 10.65, set on Jun 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.72 |
---|---|
High | 8.93 |
Low | 8.72 |
Bid | -- |
Offer | -- |
Previous close | 8.53 |
Average volume | 2.83k |
---|---|
Shares outstanding | 234.35m |
Free float | 234.14m |
P/E (TTM) | 14.32 |
Market cap | 2.10bn USD |
EPS (TTM) | 0.6234 USD |
Data delayed at least 15 minutes, as of May 31 2024 20:56 BST.
More ▼